Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 72 Publications

13 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 M{LC[GN6fG:2b4jpZ{BCe3OjeR?= M1PZZlQ5KGh? MYjEUXNQ MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIF[xNVc1VCCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIECuOlIh|ryP NFLCblQzOTV5MkW4PS=>
BAF3 M17TUWN6fG:2b4jpZ{BCe3OjeR?= NVvjUWY{PDhiaB?= NFLEd3BFVVOR MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIFyxNVk3VSCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIEKuNkDPxE1? MnPNNlE2PzJ3OEm=
BAF3 NVz1dWRMS3m2b4TvfIlkKEG|c3H5 MVq0PEBp M1TicGROW09? M1HJXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyC5aYToJGlEPTBib3[gNE4zQCEQvF2= NXHqe4l7OjF3N{K1PFk>
Kelly MYrDfZRwfG:6aXOgRZN{[Xl? MX3EUXNQ NX\wT5RbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU2WubImgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC52MjFOwG0> M2i4b|IyPTd{NUi5
SH-SY5Y NX34XXZNS3m2b4TvfIlkKEG|c3H5 MUHEUXNQ NUK4c|RoS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0hvU2m1XUBk\WyuczDlfJBz\XO|aX7nJGFNUyCIMUG3OGwhdXW2YX70JJdqfGhiSVO1NEBw\iByLkWzJO69VQ>? NInzNZEzOTV5MkW4PS=>
SMS-KCN NFPQcZNEgXSxdH;4bYMhSXO|YYm= NIO1fGZFVVOR M4j0OmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNOWy2NQ16gZ4VtdHNiZYjwdoV{e2mwZzDBUGshWjF{N{XRJI12fGGwdDD3bZRpKEmFNUCgc4YhOC57MTFOwG0> MVGyNVU4OjV6OR?=
BAF3 NFXuWolEgXSxdH;4bYMhSXO|YYm= NXzKeIhtPDhiaB?= NGS4eHdFVVOR NFv4cFFEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiVHXsMWFNUyC5aYToJGlEPTBib3[gNE4yQSEQvF2= MmHrNlE2PzJ3OEm=
3T3 MUfGeY5kfGmxbjDBd5NigQ>? MlruNUBp NEHuSZZFVVOR NYXjWnZyUW6qaXLpeIlwdiCxZjDSU24h[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFgh|ryP NWq1eI1EOjF6MUK0NVQ>
3T3-E NHP3d3JHfW6ldHnvckBCe3OjeR?= M1PZ[lEhcA>? M3LhUWROW09? NV\MVIRlUW6qaXLpeIlwdiCxZjDUTWUzKGG|c3Xzd4VlKGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkS0PEDPxE1? NYTobGg6OjF6MUK0NVQ>
A549 NVzZOFNQU2mwYYPlJGF{e2G7 NH\ZWFkyKGh? MoXUSG1UVw>? NGjSOpRKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IHOtUWVVKGurbnHz[UBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJT0ZvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByODFOwG0> NHj3c44zOThzMkSxOC=>
BAF3-BCL MWLGeY5kfGmxbjDBd5NigQ>? MoCyNUBp NYL1SYQ6TE2VTx?= M1LWNWlvcGmkaYTpc44hd2ZiQVLMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzLkG1PUDPxE1? MWOyNVgyOjRzNB?=
HEK293 NWi2[lV7TnWwY4Tpc44hSXO|YYm= Mn\lNUBp MVjEUXNQ NUT2VYM{UW6qaXLpeIlwdiCxZjDBXGwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNlk1KM7:TR?= MVWyNVgyOjRzNB?=
HEK293 NGHLdndHfW6ldHnvckBCe3OjeR?= MnmwNUBp NIPTb4tFVVOR NWXmXZZ6UW6qaXLpeIlwdiCxZjDJVkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj64PFch|ryP NY\sUXdJOjF6MUK0NVQ>
Jurkat MVXGeY5kfGmxbjDBd5NigQ>? MXOxJIg> Mn7DSG1UVw>? NH;IN2tKdmirYnn0bY9vKG:oIFzDT{Bie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj63OFEh|ryP MlzZNlE5OTJ2MUS=
KARPAS299 MVvLbY5ie2ViQYPzZZk> MWOxJIg> MVnEUXNQ MV\Jcohq[mm2aX;uJI9nKEGOSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> M3rQV|IyQDF{NEG0
PAE NHzUflNHfW6ldHnvckBCe3OjeR?= MVmxJIg> M1vFVWROW09? NEC4VVFKdmirYnn0bY9vKG:oIGTST2Ih[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuN|k6KM7:TR?= MVKyNVgyOjRzNB?=
BAF3 M4PheGZ2dmO2aX;uJGF{e2G7 MV6yMVMh\A>? NGDkUXVFVVOR M2nhd2lvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIHnud5VtcW5icnXj[ZB1d3JiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyNjZ2MzFOwG0> NInhbWMzOzd2MkK1Ni=>
KARPAS299 M1XnNWN6fG:2b4jpZ{BCe3OjeR?= MVKyMVMh\A>? NWrzcnAxTE2VTx?= MUHJR|UxRTBwME[0NkDPxE1? M2\pdVI{PzR{MkWy
EBC1 Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfhSZBmPzJiaB?= M3;ve2ROW09? NWXXUoNJUUN3ME2wMlAzOyEQvF2= M3LjUlI{QTl|M{K4
HCT116 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTSO3RoPzJiaB?= NVHCPYh5TE2VTx?= MnHWTWM2OD1zND64NkDPxE1? MWWyN|k6OzN{OB?=
MCF7 NHPtNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\kO|IhcA>? M2fUNWROW09? MVPJR|UxRTlwNUig{txO M3TPWVI{QTl|M{K4
MDA-MB-231 NUnIU4g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXwboVRPzJiaB?= M173RmROW09? NXfFc2NoUUN3ME2xNE45KM7:TR?= NWXIdGdCOjN7OUOzNlg>
MKN45 M1XRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzoO|IhcA>? M3L2V2ROW09? M4rBVmlEPTB;MD6wNVMh|ryP MW[yN|k6OzN{OB?=
NCI-H441 M4fseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nUN|czKGh? MkfYSG1UVw>? MVfJR|UxRTF5LkK1JO69VQ>? M{TsSVI{QTl|M{K4
NCI-H661 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjtfVlWPzJiaB?= M{HFdWROW09? M2[2NGlEPTB;MUGuOFch|ryP NFjTN5czOzl7M{OyPC=>
SK-MEL-28 MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LxO|czKGh? NF3p[lJFVVOR NE[2Z3dKSzVyPUGwMlk4KM7:TR?= MkPvNlM6QTN|Mki=
SKOV3 M{THbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzjO|IhcA>? NVTLRYdvTE2VTx?= M3vydGlEPTB;MUKuPFUh|ryP M4ntUFI{QTl|M{K4
SNU5 NInZeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HXeVczKGh? NYjj[4VXTE2VTx?= M2TLTWlEPTB;MD6wNVYh|ryP MlPlNlM6QTN|Mki=
NCI-H2228 NFzoZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4roVVczKGh? M4jCRmROW09? MWHJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4yOThizszN M1;INlI1PDN{OUC5
NCI-H3122 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:3NkBp MXzEUXNQ NGnQcWVKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5zMEig{txO MXyyOFQ{OjlyOR?=
NCI-H3122 M{L3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHBO|IhcA>? MVvEUXNQ NV;0OmVOUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshTzF{NknBJI12fGGwdDD3bZRpKEmFNUCgc4YhOC54MkOg{txO NILa[pUzPDR|MkmwPS=>
NCI-H3122 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLTNpA4OiCq NUSwblVkTE2VTx?= NHOzPWhKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BNOTF7Nl2gcZV1[W62IIfpeIghUUN3MDDv[kAxNjh|ODFOwG0> MXuyOFQ{OjlyOR?=
NIH-3T3 NYjucppjU2mwYYPlJGF{e2G7 M1m4S|EhcA>? NWrq[pViTE2VTx?= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJJdqdGRidInw[UBGVUx2LX\1d4VlKEGOSzDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? NF\JOWQzPDR|MkmwPS=>
NIH-3T3 M1XLb2tqdmG|ZTDBd5NigQ>? MXuxJIg> NUDkW4ZSTE2VTx?= MVTJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlY6SSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjZyNTFOwG0> MYKyOFQ{OjlyOR?=
NIH-3T3 MXnLbY5ie2ViQYPzZZk> M1;PZlEhcA>? NFHOdmdFVVOR NF[xbphKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJHMyOjB4WTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLk[yOkDPxE1? MYGyOFQ{OjlyOR?=
NIH-3T3 M2X6bGtqdmG|ZTDBd5NigQ>? M1XrRlEhcA>? NXnQdnRiTE2VTx?= M1OyV2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyQT[PIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwOESzJO69VQ>? M2jzc|I1PDN{OUC5
NIH-3T3 MWHLbY5ie2ViQYPzZZk> M17XNlEhcA>? M{noZWROW09? NXjoN3d{UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF3MmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6wNlYh|ryP NWjn[JhFOjR2M{K5NFk>
BAF3 NYnwZmR6TnWwY4Tpc44hSXO|YYm= NUTW[XpEPzJiaB?= MlG0SG1UVw>? NVHQbXU5UW6qaXLpeIlwdiCxZjDOVG0wSUyNIITyZY5{\mWldHXkJIF{e2W|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEWxJO69VQ>? NX3JOnE4OjR2Nki2N|I>
BAF3 NGDHUJZEgXSxdH;4bYMhSXO|YYm= MVe3NkBp NFHMPJVFVVOR M{nqPGlEPTB;MD65PEDPxE1? M{nOdFI1PDZ6NkOy
NIH-3T3 MV\LbY5ie2ViQYPzZZk> MYmxJIg> MXHJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIF[xNVc1VCCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjF4NTFOwG0> MYKyOFgyQTFzNh?=
NIH-3T3 MXTLbY5ie2ViQYPzZZk> NHy4TFgyKGh? MofjTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDDNVE2PllibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC52N{ig{txO Mn3INlQ5OTlzMU[=
NIH-3T3 MUnLbY5ie2ViQYPzZZk> NIfyS3EyKGh? MnfVTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVIxOlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5zNEig{txO MojwNlQ5OTlzMU[=
NIH-3T3 NGfaNmhMcW6jc3WgRZN{[Xl? MnTHNUBp MWnJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIEGxOVFVcW6|IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDNwMEO5JO69VQ>? MWCyOFgyQTFzNh?=
KARPAS299 NWTjbXJiU2mwYYPlJGF{e2G7 M2DQOVkxKG2rbh?= NIi5TVVFVVOR MoPhTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO M1LKeVI1QTByN{Ww
MKN 45 NXfJO2N1U2mwYYPlJGF{e2G7 NWnQbFJHOSCq MV3EUXNQ NXy0e3F6UW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP NXfBRndXOjR7MEC3OVA>
A549 NWfaVYJ{S3m2b4TvfIlkKEG|c3H5 MonROFghcA>? NFjDdFNFVVOR NV64[5p{UUN3MDDv[kA1NjB6NDFOwG0> MlvONlQ6ODB6M{C=
NCI-H1975 MXfDfZRwfG:6aXOgRZN{[Xl? Mne4OFghcA>? NILacWNFVVOR MmTjTWM2OCCxZjC3MlU2OSEQvF2= NHzYU4UzPDlyMEizNC=>
NCI-H1993 MVLDfZRwfG:6aXOgRZN{[Xl? MV[0PEBp MXzEUXNQ M173NWlEPTBib3[gNE4xPjFizszN MVSyOFkxODh|MB?=
NCI-H1993 NVTuSpVZSXCxdH;zbZMhSXO|YYm= M{PQTVEh|ryP NXL6TXRoOjRiaB?= M{W1TWROW09? MlfN[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= NVTrc3l5OjR7MEC4N|A>
NIH-3T3 NVvZXWRkS3m2b4TvfIlkKEG|c3H5 NXzOW5Z2PDhiaB?= NUDRT3dyTE2VTx?= M{DpZ2lEPTBib3[gNE4{PjRizszN M1PH[lI1QTByOEOw
EBC1 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjpboI4OiCq MYnEUXNQ MYPJR|UxKG:oIECuNFA3QSEQvF2= MU[yOFkxODh|MR?=
KARPAS299 NFjKVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXK3NkBp M3TwUGROW09? M2DnVmlEPTBib3[gNE4zKM7:TR?= NFTUWFkzPDlyMEizNS=>
NB1 NXvXcXB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkntTWM2OD17MT65PEBvVQ>? M2HnZ3NCVkeHUh?=
NCI-SNU-5 NFzHRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPR[lVKSzVyPUGwOU44PSCwTR?= M2O4RnNCVkeHUh?=
SR NVTvSFJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;wT2VKSzVyPUGyOk4{OSCwTR?= MkfPV2FPT0WU
SF539 NH73SXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\WdWhKSzVyPUKwOE4zPCCwTR?= NX7SdXlGW0GQR1XS
SU-DHL-1 NVXiOHBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjDTWM2OD1|M{[uPFIhdk1? MleyV2FPT0WU
SCC-3 M4npTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULvT4FiUUN3ME2zOVYvPzZibl2= NWXNRm94W0GQR1XS
DEL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq2NVZbUUN3ME2zOlkvQSCwTR?= NXvQVW1wW0GQR1XS
CTV-1 M2DHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrmd3NKSzVyPUW5Ok41QCCwTR?= MnTMV2FPT0WU
EM-2 NESxZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTZyMT6zOEBvVQ>? Mm\KV2FPT0WU
MHH-CALL-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HMPWlEPTB;NkiyMlU4KG6P NUPTS2RkW0GQR1XS
KM12 NHjLfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTdyNj65JI5O MlnoV2FPT0WU
KINGS-1 NX3nOm14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTd2OT63OUBvVQ>? MkjiV2FPT0WU
MEG-01 M1izVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L1OWlEPTB;OEW3MlY3KG6P Mn\FV2FPT0WU
BV-173 Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwMEW5PVch|ryP M{XqdnNCVkeHUh?=
LAMA-84 NFW4dYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi3S5JkUUN3ME2xMlM5Ojh{IN88US=> M4m1VXNCVkeHUh?=
KARPAS-299 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W3ZmlEPTB;MT60NFg3OSEQvF2= NX3SUW9{W0GQR1XS
K-562 NFrIW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33HPGlEPTB;MT63NlI3QSEQvF2= MWLTRW5ITVJ?
SK-LMS-1 NUThR3M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P5ZmlEPTB;MT63Olg3PyEQvF2= NFL4OnhUSU6JRWK=
MOLT-16 NHzoRnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFwOUW1O|Uh|ryP NUjCT2lCW0GQR1XS
CMK NUe2Voh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T4RmlEPTB;MT65OlE2QSEQvF2= NY\JUpQxW0GQR1XS
ST486 NI\vN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm1WoExUUN3ME2yMlQ{ODd|IN88US=> MmfaV2FPT0WU
CI-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwNEm2OVkh|ryP MYXTRW5ITVJ?
KP-N-RT-BM-1 NVv2W4pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO4TWM2OD1{LkewNVIzKM7:TR?= NWLzbZNDW0GQR1XS
ALL-PO NYS0[oQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[xTWM2OD1|LkG4NlA4KM7:TR?= MomxV2FPT0WU
KS-1 NHLVPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO1TWM2OD1|LkKxNlI2KM7:TR?= MV;TRW5ITVJ?
Becker MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXBNoF2UUN3ME20MlI{QTNizszN NX7QXGl2W0GQR1XS
GDM-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G0TGlEPTB;ND6yOFYyPyEQvF2= M{WyVHNCVkeHUh?=
BC-1 NG\3UYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHXfW9oUUN3ME20MlQ6Ojd5IN88US=> M3vYOXNCVkeHUh?=
NB14 M3K3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK1N5RKSzVyPUSuPFM2OjRizszN MkTUV2FPT0WU
NOS-1 NHz2V|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rUZmlEPTB;NT6zN|g4PCEQvF2= MY\TRW5ITVJ?
MZ1-PC NIfJVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTVwOEKxOVEh|ryP NFnT[JlUSU6JRWK=
A498 NV\Yfok6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXP3PGlbUUN3ME22MlA5PDd|IN88US=> NWnGTGtbW0GQR1XS
EW-16 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fVWGlEPTB;Nj6zO|c4OyEQvF2= M1XjcnNCVkeHUh?=
NALM-6 Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTZwNkizPFch|ryP M{HqcnNCVkeHUh?=
EB-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvG[GZKSzVyPUeuNFczOzNizszN NVTFUYRuW0GQR1XS
697 NVjsVGplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j0SmlEPTB;OT6yOFMzQSEQvF2= NFPYTohUSU6JRWK=
Ramos-2G6-4C10 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTlwNUm4OFIh|ryP M2Lmb3NCVkeHUh?=
KNS-81-FD NF7FelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzOTWM2OD17Lk[5OlU{KM7:TR?= NIrQVY5USU6JRWK=
HUTU-80 MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jxbmlEPTB;OT63OFY1OiEQvF2= MkHkV2FPT0WU
LS-411N MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFyLkC1Olch|ryP Ml3kV2FPT0WU
RPMI-8402 NV35ZppMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PyW2lEPTB;MUCuNVE3KM7:TR?= NULDWFd3W0GQR1XS
KU812 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFyLkK5PVEh|ryP MUfTRW5ITVJ?
EW-1 M{HhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFyLkS0NlUh|ryP MYrTRW5ITVJ?
HC-1 NXzjRpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFyLkS4OFQh|ryP NF7CUJlUSU6JRWK=
NB69 NILNUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\0fZVKSzVyPUGwMlUxPDNizszN MontV2FPT0WU
MFH-ino NHPve2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DlbWlEPTB;MUCuPFMxOyEQvF2= MWfTRW5ITVJ?
CCRF-CEM Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y2emlEPTB;MUGuOVk4KM7:TR?= MkLsV2FPT0WU
SK-N-DZ MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Hpd2lEPTB;MUKuNFQ{PiEQvF2= MWnTRW5ITVJ?
NCI-H720 MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF{LkG3NFUh|ryP M2G0fXNCVkeHUh?=
HCC1187 NEnmZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLjdJB3UUN3ME2xNk4zODRzIN88US=> MX3TRW5ITVJ?
IST-SL2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXTWmNRUUN3ME2xNk41QDd{IN88US=> MWHTRW5ITVJ?
KE-37 NGTuUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rpdWlEPTB;MUKuO|k3PiEQvF2= NVvXbo46W0GQR1XS
HCC1599 NFLXR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f4N2lEPTB;MUKuPVA3QSEQvF2= MYHTRW5ITVJ?
A4-Fuk M1rP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDKUHlvUUN3ME2xNk46PTh4IN88US=> MnjFV2FPT0WU
NKM-1 NGG2fJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfh[GNKSzVyPUGzMlI6OjVizszN MmTFV2FPT0WU
BE-13 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrmfZFKSzVyPUGzMlc6QDlizszN NVf1ZWZxW0GQR1XS
MV-4-11 NGTrRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\uU2lEPTB;MUSuNFMzPCEQvF2= NVjyOVl{W0GQR1XS
OPM-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLNdoRDUUN3ME2xOE41ODh3IN88US=> MmSxV2FPT0WU
KARPAS-422 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzoT4hKSzVyPUG0MlUyOjZizszN NYTaXYZZW0GQR1XS
RPMI-8226 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF2Lki5NVUh|ryP M1;rWnNCVkeHUh?=
KARPAS-45 NGXjWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvGSZVKSzVyPUG1Mlc4OTZizszN MVrTRW5ITVJ?
SK-PN-DW NVfzVVN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoKwTWM2OD1zNT64OlMyKM7:TR?= MXTTRW5ITVJ?
LC-2 NVLES|VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT3dI5bUUN3ME2xOk4yPTB4IN88US=> MYDTRW5ITVJ?
NCI-H1648 NXzEfVd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXjeWtWUUN3ME2xOk4zPTRizszN M1\NSXNCVkeHUh?=
RL95-2 NFrPeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTYTWM2OD1zNj6zPVc5KM7:TR?= NHLWbVhUSU6JRWK=
KNS-42 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\1TWM2OD1zNj63Nlc1KM7:TR?= M3nycHNCVkeHUh?=
RPMI-6666 NYn4WFlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrmcHp7UUN3ME2xOk46OjFzIN88US=> MV3TRW5ITVJ?
SIG-M5 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK0N5VKSzVyPUG3MlE6ODNizszN MnTzV2FPT0WU
VA-ES-BJ M4nkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G5RmlEPTB;MUeuO|Q2OSEQvF2= NF:5OJZUSU6JRWK=
MONO-MAC-6 M1T6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzUU4JKSzVyPUG3Mlk{OTJizszN MWrTRW5ITVJ?
LAN-6 MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLpT5ZKSzVyPUG4Mlc2PTdizszN NFnHco1USU6JRWK=
A388 NGDPdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjqTWM2OD1zOT6zNFU6KM7:TR?= MkPaV2FPT0WU
SK-NEP-1 NIPrT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJyLkKxN|Ih|ryP MnGzV2FPT0WU
TE-10 NUXo[ZdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvvTWM2OD1{MD61NlIyKM7:TR?= NI\PeIJUSU6JRWK=
HL-60 NXixcIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILJWWpKSzVyPUKwMlkxQTlizszN M{jBbnNCVkeHUh?=
MC116 M{mxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlmwTWM2OD1{MT63NlIyKM7:TR?= M336U3NCVkeHUh?=
SW962 M2PwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTCOFBKSzVyPUKxMlc6OTVizszN M3TUSXNCVkeHUh?=
NOMO-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz3SZRKSzVyPUKyMlY2PjRizszN NFHF[YhUSU6JRWK=
CTB-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJ{Lki2O|Eh|ryP M33i[3NCVkeHUh?=
MRK-nu-1 M1n0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTpSWNLUUN3ME2yNk46ODd2IN88US=> MV;TRW5ITVJ?
GR-ST NF[zeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHVTWM2OD1{Mz63OkDPxE1? NV20fWdVW0GQR1XS
HH NYfTVlhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\UfGlEPTB;MkSuNFA{KM7:TR?= MoTwV2FPT0WU
NCI-H1963 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfhUWM4UUN3ME2yOE4xPzh{IN88US=> Moi5V2FPT0WU
QIMR-WIL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H5cmlEPTB;MkSuPFc4OiEQvF2= M{P1dHNCVkeHUh?=
CGTH-W-1 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W1N2lEPTB;MkWuNFczOyEQvF2= MlnOV2FPT0WU
LP-1 M2X6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu1TWM2OD1{NT62OVUyKM7:TR?= Mn[3V2FPT0WU
NCI-H748 NWrnT3M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfjTWM2OD1{Nj61NVM4KM7:TR?= Mom1V2FPT0WU
PF-382 NFzWe4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTYTWM2OD1{Nz6yNlI{KM7:TR?= M{O4cnNCVkeHUh?=
ATN-1 NEX5eplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHGdXlKSzVyPUK3MlM4OzJizszN NY\pN2p3W0GQR1XS
L-540 NH7wT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTuboFxUUN3ME2yO{43PDV7IN88US=> M3fTdnNCVkeHUh?=
LXF-289 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHCOFJKSzVyPUK3Mlc2OTlizszN M4qxfXNCVkeHUh?=
LS-513 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ6LkG4NFch|ryP NX3yOJY6W0GQR1XS
NCI-H1581 NFfMb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fyTmlEPTB;M{CuN|k4PiEQvF2= NE\0XW1USU6JRWK=
ES6 M3rkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXrWJh3UUN3ME2zNE43QDl7IN88US=> NGfmPZNUSU6JRWK=
SW982 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNyLki1OlYh|ryP NV7DepNGW0GQR1XS
DOHH-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4faWGlEPTB;M{GuOVg6OyEQvF2= M2fTRXNCVkeHUh?=
DB MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT5TWM2OD1|Mz65OFMyKM7:TR?= M1TsWXNCVkeHUh?=
MPP-89 M1[0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXYNJpCUUN3ME2zOE4yPzV4IN88US=> NXHRe2w6W0GQR1XS
LB831-BLC NIWzZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTN2LkWxPFQh|ryP NGjDNVlUSU6JRWK=
NB5 NInCWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL4PFQ6UUN3ME2zOE45PTN3IN88US=> Mm\6V2FPT0WU
GB-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2yTWM2OD1|NT6wOFY6KM7:TR?= MofBV2FPT0WU
TE-15 NIXkdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXWTWM2OD1|NT6yNlM5KM7:TR?= Ml\QV2FPT0WU
LC4-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLjTWM2OD1|NT6zPFQ4KM7:TR?= MnzDV2FPT0WU
NCI-H747 NHjMS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTXWJRKSzVyPUO2MlE{PjlizszN MojmV2FPT0WU
NTERA-S-cl-D1 NUXSeotXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnMTWM2OD1|OD63N|Q4KM7:TR?= NXTkV4lnW0GQR1XS
SK-MM-2 NIr3ZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTRyLkGxOFYh|ryP NWXpZmp3W0GQR1XS
TGW MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\rTWM2OD12MT6wOVY{KM7:TR?= M{W3W3NCVkeHUh?=
ONS-76 MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfETWM2OD12Mj60PFg{KM7:TR?= NVfkN5ViW0GQR1XS
CPC-N MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTR{Lkm5O|Eh|ryP NFTjcGVUSU6JRWK=
ES4 MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\UXYMxUUN3ME20OE41OTV|IN88US=> MmDkV2FPT0WU
Daudi M4\0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\qc2dwUUN3ME20OU4xQDJ5IN88US=> NHHLbm5USU6JRWK=
MOLT-4 NX3TPFlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTR3LkC4OVMh|ryP M1HuTXNCVkeHUh?=
HT-144 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M133OWlEPTB;NE[uO|I3KM7:TR?= MWTTRW5ITVJ?
SW872 M374Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPyWmxKSzVyPUS4MlE6OzNizszN M2jzZ3NCVkeHUh?=
D-283MED MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjiVFNKSzVyPUS4MlM2PDJizszN MnnhV2FPT0WU
NCI-H2126 NHXGfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX4e|dKSzVyPUS4Mlg1PzZizszN NIXte2NUSU6JRWK=
NCI-SNU-16 NIn3cmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTR7LkKxOFMh|ryP NGPlTHRUSU6JRWK=
CESS M3zoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTLOYJTUUN3ME20PU42ODh6IN88US=> NW[ybol{W0GQR1XS
A101D MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR7Lkm3N|Yh|ryP MY\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID